.
MergerLinks Header Logo

Announced

Completed

Merck completed the acquisition of ArQule for $2.7bn.

Financials

Edit Data
Transaction Value£2,054m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Cross Border

treatment development

Biotechnology

Acquisition

Majority

Public

United States

biopharmaceuticals

rare diseases

Friendly

cancer treatment

Single Bidder

Tender Offer

Completed

Synopsis

Edit

Merck, a German multinational pharmaceutical, chemical and life sciences company, completed the acquisition of ArQule, a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, for $2.7bn. "ArQule’s focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties. This acquisition strengthens Merck’s pipeline with the addition of these strategic assets including, most notably, ARQ 531, a compelling candidate for the treatment of B-cell malignancies," Roger M. Perlmutter, Merck Research Laboratories President.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US